SCHEMBL10040988

SCHEMBL10040988

CON1C(=O)c2cccc3cccc(c23)C1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.60
▸ ERCC1 P07992 1/20 0.57
▸ FEN1 P39748 1/20 0.57
▸ ERCC4 Q92889 1/20 0.57
▸ ALDH1A1 P00352 9/20 0.56
▸ KDM4E B2RXH2 9/20 0.56
▸ HPGD P15428 7/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ CYP1B1 Q16678 1/20 0.56
▸ LMNA P02545 2/20 0.56
▸ MAPT P10636 3/20 0.54
▸ HTT P42858 1/20 0.54
▸ GAA P10253 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ CES2 O00748 1/20 0.50
▸ BCHE P06276 1/20 0.50
▸ CES1 P23141 1/20 0.50
▸ MCL1 Q07820 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13495341 0.86 ALDH1A1 (0.50) TDP1ERCC1FEN1ERCC4ALDH1A1
SCHEMBL13495351 0.85 TDP1 (0.47) TDP1ERCC1FEN1ERCC4ALDH1A1
SCHEMBL13495348 0.84 RAD52 (0.60) TDP1ALDH1A1KDM4EHPGDMEN1
SCHEMBL13495362 0.84 BRD1 (0.52) TDP1ERCC1FEN1ERCC4ALDH1A1
SCHEMBL28901731 0.83 ERCC1 (0.61) TDP1ERCC1FEN1ERCC4ALDH1A1
SCHEMBL13495347 0.82 KMT2A (0.50) TDP1ALDH1A1KDM4EHPGDMEN1
SCHEMBL13495349 0.82 TDP1 (0.44) TDP1ERCC1FEN1ERCC4ALDH1A1
SCHEMBL13495355 0.82 TDP1 (0.44) TDP1ERCC1FEN1ERCC4ALDH1A1
SCHEMBL12540917 0.81 NPC1 (0.42) TDP1ALDH1A1KDM4EHPGDMEN1
SCHEMBL30219494 0.81 GAA (0.52) TDP1ALDH1A1KDM4EHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110041317-B Naphthalimide fluorescent probe and preparation and application thereof 福州大学 2022-01-04 — — CN claimed
US-12036078-B2 Oral products and methods for producing the same PolySpectra, Inc. (US) 2024-07-16 — — US disclosed
US-11725077-B2 Olefin metathesis photopolymers PolySpectra, Inc. (US) 2023-08-15 — — US disclosed
CN-110041317-B Naphthalimide fluorescent probe and preparation and application thereof 福州大学 2022-01-04 — — CN disclosed
US-20170130028-A1 RUBBER COMPOSITION AND VULCANIZATION AID SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-11 — — US disclosed
US-20170130028-A1 RUBBER COMPOSITION AND VULCANIZATION AID SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-11 — — US disclosed
US-8715918-B2 Thick film resists AZ ELECTRONIC MATERIALS USA CORP. (US) 2014-05-06 — — US disclosed
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 — — US disclosed
US-20120043480-A1 UV-DOSE INDICATOR FILMS BASF SE (DE) 2012-02-23 — — US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 — — US disclosed
US-20090081589-A1 THICK FILM RESISTS MERCK PATENT GMBH (DE) 2009-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC TDP1 2370/4885ERCC1 1768/4885FEN1 1143/4885
US-20170130028-A1 RUBBER COMPOSITION AND VULCANIZATION AID CCNA1, RCN1, RER1 TDP1 2472/4885ERCC1 36/4885FEN1 2634/4885
US-12036078-B2 Oral products and methods for producing the same CROCC, RPAP1, RUVBL1 TDP1 1727/4885ERCC1 303/4885FEN1 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback